<DOC>
	<DOCNO>NCT01849159</DOCNO>
	<brief_summary>Actively develop stem cell ( SCs ) transplantation technique cause natural interest problem regeneration lung . Numerous experimental study prove benefit different type SCs experimental model pulmonary emphysema ( PE ) . G. Zhen et al . show transplantation mesenchymal stem cell ( MSCs ) rat papain-induced emphysema lead migration lung , differentiation type 2 alveolocytes , inhibition apoptosis prevention PE . K. Schweitzer et al . proved activity inflammation airway , alveolocytes endothelial cell apoptosis decrease adipose SCs intravenous administration mouse emphysema cause chronic exposure tobacco smoke VEGF receptor blockade . The study E.P . Ingenito et al . find endobronchial installed MSCs engraft alveolar wall peribronchial interstitium release integrins , extracellular matrix component ( collagen IV , laminin fibrillin ) , platelet-derived growth factor receptor transform growth factor β2 . Our study also find reliable deterrent effect allogeneic bone marrow MSCs development elastase-induced emphysema rat different term transplantation . After success pilot study start clinical trial . Currently , website http : //www . ClinicalTrials.gov report three study evaluate efficacy safety MSC transplantation patient COPD emphysema . Two already complete result first pilot project publish . Authors example 4 patient show complete absence adverse effect , improve quality life stability functional parameter 12 month start treatment One problem MSC transplantation patient respiratory failure accelerate apoptosis transplant cell influence proinflammatory cytokine oxidative stress . Since prove precondition MSCs hypoxia increase survival hypoxic condition , increase expression growth factor antiinflammatory cytokine , suppose MSCs grown hypoxic medium may significant positive effect disease .</brief_summary>
	<brief_title>Clinical Study Efficacy Safety Application Allogeneic Mesenchymal ( Stromal ) Cells Bone Marrow , Cultured Under Hypoxia Treatment Patients With Severe Pulmonary Emphysema</brief_title>
	<detailed_description />
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>HRCTconfirmed diagnosis lung emphysema two independent radiologist postbronchodilator FEV1/FVC ratio &lt; 0.7 postbronchodilator FEV1 % predict value ≥ 20 % &lt; 50 % age 35 75 year , either sex , race current exsmoker , cigarette smoke history ≥ 10 packyears • asthma clinically relevant lung disease COPD ( e.g . restrictive lung disease , sarcoidosis , tuberculosis , idiopathic pulmonary fibrosis , lung cancer ) α1Antitrypsin deficiency Presence bulla ( 10 cm diameter ) active infection within 4 week screen significant exacerbation COPD require mechanical ventilation within 4 week screen clinically relevant uncontrolled medical condition associate COPD document history uncontrolled heart failure pulmonary hypertension due leave heart condition Subject evidence active malignancy , prior history active malignancy Subject life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Hypoxia</keyword>
	<keyword>Emphysema</keyword>
</DOC>